Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Edwards Lifesciences's Business Segments
Edwards Lifesciences's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
4
Largest Segment
United States
Total Revenue
$ 1,741
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- United States57.6%
- Europe25.2%
- Rest of World11.6%
- Japan5.5%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| United States | $ 1,004 | 57.6% |
| Europe | $ 440 | 25.2% |
| Rest of World | $ 202 | 11.6% |
1 more segments available
Sign in to unlock the full Edwards Lifesciences dataset.
Revenue by Product & Service Category - Q2 FY2026
- Transcatheter Aortic Valve Replacement72.3%
- Surgical16.3%
- Transcatheter Mitral and Tricuspid Therapies11.4%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Transcatheter Aortic Valve Replacement | $ 1,258 | 72.3% |
| Surgical | $ 284 | 16.3% |
| Transcatheter Mitral and Tricuspid Therapies | $ 199 | 11.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Edwards Lifesciences
Business Description of Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a prominent medical technology company that specializes in developing and manufacturing innovative solutions for the treatment of structural heart disease and the management of critically ill patients. Established with a commitment to advancing heart valve technologies, the company has emerged as a global leader in this field, particularly in the areas of tissue heart valves and repair products designed to address diseased or defective heart valves.
Product Overview
The company’s extensive product portfolio is categorized into three key areas:
1. Surgical Heart Valve Therapy: This segment includes surgical heart valves and associated cardiac surgery systems. Edwards Lifesciences provides an array of durable, reliable heart valves crafted from bioprosthetic materials, which are designed to mimic the function of natural heart valves while offering durability and minimal risk of rejection. The company places a strong emphasis on surgical innovation, equipping surgeons with advanced tools and solutions that enhance the safety and efficacy of heart valve surgeries.
2. Transcatheter Heart Valves: Edwards Lifesciences has pioneered the development of minimally invasive transcatheter heart valve replacement technology. This segment addresses a significant clinical need for patients with aortic stenosis, particularly for those who are considered high-risk surgical candidates. Utilizing advanced technologies, the company offers transcatheter aortic valve replacement (TAVR) solutions, which allow for valve implantation via a catheter rather than traditional open-heart surgery. This innovation significantly reduces recovery time and improves patient outcomes.
3. Critical Care: The critical care segment focuses on hemodynamic monitoring and other advanced technologies that support patient care in intensive care units (ICUs) and during surgical procedures. The companys hemodynamic monitoring systems provide real-time data on a patients cardiovascular status, enabling healthcare professionals to make informed decisions regarding patient management. The integration of advanced monitoring technologies enhances the overall quality of care, particularly in high-stakes environments.
Market Position and Strategy
Edwards Lifesciences is recognized as a leader in the global market for heart valve therapies and monitoring solutions. The company’s strong emphasis on research and development has propelled it to the forefront of innovation in cardiovascular technology. Continuous investments in R&D enable the development of new products and enhancements to existing technologies, directly responding to the evolving needs of patients and clinicians.
With the rise in global cardiovascular disease prevalence—and the fact that cardiovascular disease remains the leading cause of death worldwide—Edwards Lifesciences is strategically positioned to address this critical healthcare challenge. The company works closely with healthcare providers to implement advanced treatment options that improve patient care and outcomes.
Commitment to Quality and Education
Edwards Lifesciences prioritizes quality in both its products and services. The company adheres to stringent regulatory standards and maintains a robust quality assurance framework to ensure that its products meet or exceed safety and performance benchmarks. In addition, Edwards Lifesciences is dedicated to providing educational resources and training to medical professionals, ensuring they are equipped to utilize the latest technologies effectively in clinical practice.
Conclusion
As a pioneering force in the medical technology industry, Edwards Lifesciences Corporation stands at the vanguard of innovations that address some of the most pressing challenges in cardiovascular health care. Its focus on advanced heart valve therapies and critical care solutions continues to save lives and enhance the quality of care for patients suffering from structural heart disease and critical illness, reinforcing its commitment to improving the health of those it serves worldwide.
Edwards Lifesciences Corporation is a prominent medical technology company that specializes in developing and manufacturing innovative solutions for the treatment of structural heart disease and the management of critically ill patients. Established with a commitment to advancing heart valve technologies, the company has emerged as a global leader in this field, particularly in the areas of tissue heart valves and repair products designed to address diseased or defective heart valves.
Product Overview
The company’s extensive product portfolio is categorized into three key areas:
1. Surgical Heart Valve Therapy: This segment includes surgical heart valves and associated cardiac surgery systems. Edwards Lifesciences provides an array of durable, reliable heart valves crafted from bioprosthetic materials, which are designed to mimic the function of natural heart valves while offering durability and minimal risk of rejection. The company places a strong emphasis on surgical innovation, equipping surgeons with advanced tools and solutions that enhance the safety and efficacy of heart valve surgeries.
2. Transcatheter Heart Valves: Edwards Lifesciences has pioneered the development of minimally invasive transcatheter heart valve replacement technology. This segment addresses a significant clinical need for patients with aortic stenosis, particularly for those who are considered high-risk surgical candidates. Utilizing advanced technologies, the company offers transcatheter aortic valve replacement (TAVR) solutions, which allow for valve implantation via a catheter rather than traditional open-heart surgery. This innovation significantly reduces recovery time and improves patient outcomes.
3. Critical Care: The critical care segment focuses on hemodynamic monitoring and other advanced technologies that support patient care in intensive care units (ICUs) and during surgical procedures. The companys hemodynamic monitoring systems provide real-time data on a patients cardiovascular status, enabling healthcare professionals to make informed decisions regarding patient management. The integration of advanced monitoring technologies enhances the overall quality of care, particularly in high-stakes environments.
Market Position and Strategy
Edwards Lifesciences is recognized as a leader in the global market for heart valve therapies and monitoring solutions. The company’s strong emphasis on research and development has propelled it to the forefront of innovation in cardiovascular technology. Continuous investments in R&D enable the development of new products and enhancements to existing technologies, directly responding to the evolving needs of patients and clinicians.
With the rise in global cardiovascular disease prevalence—and the fact that cardiovascular disease remains the leading cause of death worldwide—Edwards Lifesciences is strategically positioned to address this critical healthcare challenge. The company works closely with healthcare providers to implement advanced treatment options that improve patient care and outcomes.
Commitment to Quality and Education
Edwards Lifesciences prioritizes quality in both its products and services. The company adheres to stringent regulatory standards and maintains a robust quality assurance framework to ensure that its products meet or exceed safety and performance benchmarks. In addition, Edwards Lifesciences is dedicated to providing educational resources and training to medical professionals, ensuring they are equipped to utilize the latest technologies effectively in clinical practice.
Conclusion
As a pioneering force in the medical technology industry, Edwards Lifesciences Corporation stands at the vanguard of innovations that address some of the most pressing challenges in cardiovascular health care. Its focus on advanced heart valve therapies and critical care solutions continues to save lives and enhance the quality of care for patients suffering from structural heart disease and critical illness, reinforcing its commitment to improving the health of those it serves worldwide.
Edwards Lifesciences Corporation Overview
Edwards Lifesciences Corporation is a globally recognized leader in cardiovascular care, particularly known for its advanced technology in heart valve therapy and critical care monitoring. The company is dedicated to developing innovative medical devices and services that uniquely address various cardiovascular conditions, making it a trusted entity in the medical device industry. Edwards Lifesciences continuously seeks to enhance patient outcomes with its state-of-the-art solutions.
1. Surgical Heart Valve Therapy
Product Segments:
Edwards Lifesciences is prominently known for its surgical heart valves, which play a crucial role in the replacement or repair of diseased heart valves. The offerings in this segment include:
- Carpentier-Edwards PERIMOUNT Valves:
- This flagship line features tissue heart valves meticulously crafted from pericardial tissue. Notably, the PERIMOUNT Magna Ease valve is designed for aortic and mitral valve replacements and is renowned for its durability and performance. These valves are the most prescribed tissue heart valves globally, being associated with excellent clinical outcomes.
- Heart Valve Repair Products:
- Beyond replacement valves, Edwards Lifesciences leads in heart valve repair therapies. The company provides annuloplasty rings and various systems that facilitate valve repair procedures, expanding the range of treatment options for patients with valve dysfunction.
Less Invasive Surgery Solutions:
With a growing focus on minimally invasive surgical techniques, Edwards Lifesciences has developed various innovative solutions designed to minimize patient recovery time and enhance surgical outcomes:
- ThruPort Systems:
- This system allows for minimally invasive valve surgeries (MIVS) through small incisions. The ThruPort Systems encompass a comprehensive range of tools, including soft tissue retractors, aortic occlusion devices, coronary sinus catheters, and specialized instrumentation aimed at enhancing surgical precision.
- Comprehensive Training and Support:
- Edwards Lifesciences offers extensive training programs for surgical teams on MIVS techniques, alongside clinical support in operating rooms to ensure effective implementation of these advanced methods.
Transcatheter Heart Valves
Edwards Lifesciences has significantly expanded its product offerings in the transcatheter heart valve category, focusing on catheter-based solutions to address heart valve diseases:
- Edwards SAPIEN Transcatheter Aortic Heart Valves:
- The SAPIEN valve received FDA approval for transfemoral delivery in 2011 for patients considered inoperable, followed by subsequent approvals for high-risk patients in 2012. The SAPIEN valve utilizes state-of-the-art delivery systems, allowing for beating heart procedures that significantly improve patient outcomes.
- SAPIEN XT Valve:
- Building upon the success of the original SAPIEN valve, Edwards Lifesciences introduced the SAPIEN XT valve, featuring advanced technology for improved delivery systems and a lower profile design, thus enhancing accessibility during procedures. This device is available in select international markets and is undergoing clinical trials in the United States.
Critical Care Products
Edwards Lifesciences is also a leading provider of hemodynamic monitoring systems, crucial for assessing heart function and patient management in critical care settings:
- Hemodynamic Monitoring Systems:
- The companys sophisticated systems are essential for managing critically ill patients, particularly in surgical settings such as open-heart operations and significant vascular surgeries.
- Key Products in Critical Care:
- Swan-Ganz Pulmonary Artery Catheter: This vital tool is used for monitoring pulmonary artery pressures.
- PreSep Continuous Venous Oximetry Catheter: Designed to assess central venous oxygen saturation.
- FloTrac Monitoring System: A minimally invasive system providing continuous cardiac output monitoring.
- VolumeView Sensor-Catheter Set: Offers volumetric hemodynamic data for critically ill patients.
- EV1000 Clinical Monitoring Platform: Integrates multiple sensors while displaying critical physiological parameters.
Innovation in Non-Invasive Monitoring:
In response to the evolving needs of healthcare providers, the company expanded its critical care portfolio in 2012 through the acquisition of non-invasive hemodynamic monitoring products, integrating these innovations into existing clinical platforms for optimal patient monitoring capabilities.
Infection Prevention Solutions:
Edwards Lifesciences has also prioritized infection prevention by developing disposable pressure monitoring devices and innovative closed blood sampling systems, significantly reducing infection risks for patients and healthcare providers alike.
Peripheral Vascular Products
Recognizing the vital connection between cardiovascular health and peripheral vascular conditions, Edwards Lifesciences provides solutions for managing a range of endolumenal occlusive diseases:
- Fogarty Embolectomy Catheters:
- As a long-standing industry standard, these catheters are employed for the removal of blood clots from peripheral vessels, having proven their reliability and efficacy over four decades.
- Additional Treatments:
- The company also offers a variety of catheter-based solutions that focus on the management of occlusive diseases, ensuring comprehensive cardiovascular care.
Conclusion
Edwards Lifesciences Corporation continues to maintain its position as a leader in the cardiovascular medical device industry through relentless innovation and a diverse range of advanced product offerings. With an unwavering commitment to enhancing patient care, the company’s extensive portfolio—including surgical heart valve therapies, transcatheter solutions, critical care monitoring systems, and peripheral vascular products—positions it as a pivotal force in advancing cardiovascular healthcare.
Edwards Lifesciences Corporation is a globally recognized leader in cardiovascular care, particularly known for its advanced technology in heart valve therapy and critical care monitoring. The company is dedicated to developing innovative medical devices and services that uniquely address various cardiovascular conditions, making it a trusted entity in the medical device industry. Edwards Lifesciences continuously seeks to enhance patient outcomes with its state-of-the-art solutions.
1. Surgical Heart Valve Therapy
Product Segments:
Edwards Lifesciences is prominently known for its surgical heart valves, which play a crucial role in the replacement or repair of diseased heart valves. The offerings in this segment include:
- Carpentier-Edwards PERIMOUNT Valves:
- This flagship line features tissue heart valves meticulously crafted from pericardial tissue. Notably, the PERIMOUNT Magna Ease valve is designed for aortic and mitral valve replacements and is renowned for its durability and performance. These valves are the most prescribed tissue heart valves globally, being associated with excellent clinical outcomes.
- Heart Valve Repair Products:
- Beyond replacement valves, Edwards Lifesciences leads in heart valve repair therapies. The company provides annuloplasty rings and various systems that facilitate valve repair procedures, expanding the range of treatment options for patients with valve dysfunction.
Less Invasive Surgery Solutions:
With a growing focus on minimally invasive surgical techniques, Edwards Lifesciences has developed various innovative solutions designed to minimize patient recovery time and enhance surgical outcomes:
- ThruPort Systems:
- This system allows for minimally invasive valve surgeries (MIVS) through small incisions. The ThruPort Systems encompass a comprehensive range of tools, including soft tissue retractors, aortic occlusion devices, coronary sinus catheters, and specialized instrumentation aimed at enhancing surgical precision.
- Comprehensive Training and Support:
- Edwards Lifesciences offers extensive training programs for surgical teams on MIVS techniques, alongside clinical support in operating rooms to ensure effective implementation of these advanced methods.
Transcatheter Heart Valves
Edwards Lifesciences has significantly expanded its product offerings in the transcatheter heart valve category, focusing on catheter-based solutions to address heart valve diseases:
- Edwards SAPIEN Transcatheter Aortic Heart Valves:
- The SAPIEN valve received FDA approval for transfemoral delivery in 2011 for patients considered inoperable, followed by subsequent approvals for high-risk patients in 2012. The SAPIEN valve utilizes state-of-the-art delivery systems, allowing for beating heart procedures that significantly improve patient outcomes.
- SAPIEN XT Valve:
- Building upon the success of the original SAPIEN valve, Edwards Lifesciences introduced the SAPIEN XT valve, featuring advanced technology for improved delivery systems and a lower profile design, thus enhancing accessibility during procedures. This device is available in select international markets and is undergoing clinical trials in the United States.
Critical Care Products
Edwards Lifesciences is also a leading provider of hemodynamic monitoring systems, crucial for assessing heart function and patient management in critical care settings:
- Hemodynamic Monitoring Systems:
- The companys sophisticated systems are essential for managing critically ill patients, particularly in surgical settings such as open-heart operations and significant vascular surgeries.
- Key Products in Critical Care:
- Swan-Ganz Pulmonary Artery Catheter: This vital tool is used for monitoring pulmonary artery pressures.
- PreSep Continuous Venous Oximetry Catheter: Designed to assess central venous oxygen saturation.
- FloTrac Monitoring System: A minimally invasive system providing continuous cardiac output monitoring.
- VolumeView Sensor-Catheter Set: Offers volumetric hemodynamic data for critically ill patients.
- EV1000 Clinical Monitoring Platform: Integrates multiple sensors while displaying critical physiological parameters.
Innovation in Non-Invasive Monitoring:
In response to the evolving needs of healthcare providers, the company expanded its critical care portfolio in 2012 through the acquisition of non-invasive hemodynamic monitoring products, integrating these innovations into existing clinical platforms for optimal patient monitoring capabilities.
Infection Prevention Solutions:
Edwards Lifesciences has also prioritized infection prevention by developing disposable pressure monitoring devices and innovative closed blood sampling systems, significantly reducing infection risks for patients and healthcare providers alike.
Peripheral Vascular Products
Recognizing the vital connection between cardiovascular health and peripheral vascular conditions, Edwards Lifesciences provides solutions for managing a range of endolumenal occlusive diseases:
- Fogarty Embolectomy Catheters:
- As a long-standing industry standard, these catheters are employed for the removal of blood clots from peripheral vessels, having proven their reliability and efficacy over four decades.
- Additional Treatments:
- The company also offers a variety of catheter-based solutions that focus on the management of occlusive diseases, ensuring comprehensive cardiovascular care.
Conclusion
Edwards Lifesciences Corporation continues to maintain its position as a leader in the cardiovascular medical device industry through relentless innovation and a diverse range of advanced product offerings. With an unwavering commitment to enhancing patient care, the company’s extensive portfolio—including surgical heart valve therapies, transcatheter solutions, critical care monitoring systems, and peripheral vascular products—positions it as a pivotal force in advancing cardiovascular healthcare.